Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

439
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
439
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incorporating Teamwork Strategies for Internal Medicine Residents in Training to Mitigate Hospital Utilization for High-Risk Patients.

Rhode Island medical journal (2013)·2026
Same author

Discovery of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 Main Protease through Computer-Aided Drug Design.

Journal of medicinal chemistry·2025
Same author

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.

Molecular cancer therapeutics·2024
Same author

Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1.

Journal of medicinal chemistry·2024
Same author

Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity.

Bioorganic & medicinal chemistry·2024
Same author

Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.

Journal of medicinal chemistry·2024

Related Experiment Video

Updated: Mar 5, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

12.0K

Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure.

Marion Lanier1, Jason Pickens1, Simone V Bigi1

  • 1Departments of Medicinal Chemistry, Drug Metabolism Pharmacokinetics, Structural Biology, and Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals , 10410 Science Center Drive, San Diego, California 92121, United States.

ACS Medicinal Chemistry Letters
|March 25, 2017
PubMed
Summary
This summary is machine-generated.

A novel inhibitor targeting apoptosis signal-regulating kinase 1 (ASK1) effectively reduced cardiac injury in a heart model. This discovery offers a potential therapeutic strategy for ischemia/reperfusion injury.

Keywords:
Apoptosis signal-regulating kinase 1 (ASK1)cardiac injurystructure-based drug design (SBDD)

More Related Videos

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.7K
Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.6K

Related Experiment Videos

Last Updated: Mar 5, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

12.0K
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.7K
Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.6K

Area of Science:

  • Biochemistry
  • Cardiovascular Biology
  • Drug Discovery

Background:

  • Apoptosis signal-regulating kinase 1 (ASK1) is implicated in acute ischemia/reperfusion (I/R) injury.
  • Mitogen-activated protein kinase (MAPK) pathways play a role in cellular stress responses.

Purpose of the Study:

  • To develop and evaluate a novel inhibitor of ASK1 for potential therapeutic applications in cardiac I/R injury.
  • To investigate the efficacy of a structure-based designed ASK1 inhibitor in reducing infarct size.

Main Methods:

  • Structure-based drug design was employed to deconstruct and reoptimize a known ASK1 inhibitor.
  • A lead compound was identified and tested for its inhibitory activity against the MAP3K pathway.
  • The compound's efficacy was assessed in an isolated perfused heart model of cardiac injury.

Main Results:

  • A novel lead compound targeting ASK1 was successfully identified through structure-based drug design.
  • The lead compound demonstrated potent inhibition of the MAP3K pathway.
  • Significant reduction in infarct size was observed in the isolated perfused heart model.

Conclusions:

  • The developed ASK1 inhibitor shows promise as a therapeutic agent for mitigating cardiac I/R injury.
  • Targeting ASK1 with specific inhibitors is a viable strategy for managing cardiovascular damage.
  • Further research is warranted to explore the clinical potential of this ASK1 inhibitor.